

Leverett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.9	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	8	7.2	111.4	(48.0-219.5)	Female	0	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.3	nc	(nc-nc)
Male	3	3.0	nc	(nc-nc)	<u>Ovary</u>				
Female	4	2.2	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.5	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	9	8.5	105.3	(48.1-200.0)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.7	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.4	nc	(nc-nc)	Female	3	1.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.4	nc	(nc-nc)	Male	27	27.4	98.7	(65.0-143.6)
Female	0	0.1	nc	(nc-nc)	Female	24	21.6	111.2	(71.2-165.5)
<u>Lung and Bronchus</u>									
Male	4	3.8	nc	(nc-nc)					
Female	1	2.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lexington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	38	43.1	88.3	(62.5-121.2)	Male	28	21.4	130.8	(86.9-189.1)
Female	12	16.2	74.1	(38.2-129.4)	Female	24	17.2	139.4	(89.3-207.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	7.2	138.7	(66.4-255.0)	Male	4	6.2	nc	(nc-nc)
Female	6	6.7	89.3	(32.6-194.4)	Female	4	5.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.3	nc	(nc-nc)	Male	26	20.7	125.4	(81.9-183.7)
Female	138	159.1	86.8	(72.9-102.5)	Female	21	20.3	103.6	(64.1-158.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	6.3	nc	(nc-nc)	Male	8	15.4	52.0	(22.4-102.4)
<u>Colon / Rectum</u>					Female	9	8.1	111.7	(51.0-212.1)
Male	61	64.5	94.5	(72.3-121.4)	<u>Ovary</u>				
Female	38	67.4	56.4	(39.9-77.4)	Female	18	16.9	106.6	(63.1-168.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	10.5	86.1	(39.3-163.4)	Male	6	12.2	49.2	(18.0-107.1)
Female	0	3.2	nc	(nc-nc)	Female	9	14.2	63.2	(28.8-120.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	2.6	nc	(nc-nc)	Male	183	169.5	108.0	(92.9-124.8)
Female	2	2.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	10.9	nc	(nc-nc)
Male	19	17.0	112.0	(67.4-174.8)	Female	5	7.2	69.8	(22.5-162.8)
Female	7	11.4	61.2	(24.5-126.2)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.8	nc	(nc-nc)
Male	2	7.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	2.0	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
<u>Leukemia</u>					Female	20	12.3	162.7	(99.4-251.3)
Male	16	12.7	126.0	(72.0-204.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	11.3	97.6	(48.7-174.7)	Female	41	32.4	126.7	(90.9-171.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	7.9	75.6	(27.6-164.5)	Male	505	556.1	90.8	(83.1-99.1)
Female	4	3.2	nc	(nc-nc)	Female	464	539.6	86.0	(78.3-94.2)
<u>Lung and Bronchus</u>									
Male	49	80.8	60.7	(44.9-80.2)					
Female	52	75.5	68.9	(51.4-90.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Leyden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.7	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	3.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.3	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	10.5	47.8	(15.4-111.6)
Female	0	0.0	nc	(nc-nc)	Female	6	8.3	71.9	(26.3-156.6)
<u>Lung and Bronchus</u>									
Male	0	1.4	nc	(nc-nc)					
Female	1	1.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lincoln

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	7.7	nc	(nc-nc)	Male	10	4.3	231.0	(110.6-424.8)
Female	0	2.5	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.6	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
Female	30	29.0	103.4	(69.7-147.6)	Female	3	3.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.4	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.4	nc	(nc-nc)
Male	13	11.8	109.9	(58.4-187.9)	<u>Ovary</u>				
Female	13	9.8	132.2	(70.3-226.1)	Female	2	3.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.0	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	0.7	nc	(nc-nc)	Male	38	32.0	118.9	(84.1-163.2)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.0	nc	(nc-nc)
Male	2	3.3	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.2	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	6	3.0	198.3	(72.4-431.7)
Male	1	2.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.9	nc	(nc-nc)	Female	4	5.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.5	nc	(nc-nc)	Male	97	105.8	91.7	(74.3-111.8)
Female	0	0.5	nc	(nc-nc)	Female	83	92.5	89.7	(71.5-111.2)
<u>Lung and Bronchus</u>									
Male	4	14.9	nc	(nc-nc)					
Female	7	12.3	57.0	(22.8-117.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Littleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	8.0	99.6	(42.9-196.3)	Male	5	4.6	109.7	(35.3-256.0)
Female	4	2.8	nc	(nc-nc)	Female	9	3.7	240.4	(109.7-456.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	1.6	426.3	(170.8-878.3)	Male	2	1.2	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	5	4.3	116.3	(37.5-271.5)
Female	37	31.7	116.7	(82.1-160.8)	Female	3	3.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.5	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.5	nc	(nc-nc)
Male	15	12.3	121.9	(68.2-201.0)	<u>Ovary</u>				
Female	11	11.6	94.6	(47.2-169.4)	Female	4	3.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.1	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	33	33.0	100.0	(68.8-140.4)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.1	nc	(nc-nc)
Male	3	3.5	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.3	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	3	3.2	nc	(nc-nc)
Male	3	2.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.2	nc	(nc-nc)	Female	6	6.3	94.6	(34.5-205.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.6	nc	(nc-nc)	Male	116	109.8	105.7	(87.3-126.7)
Female	0	0.6	nc	(nc-nc)	Female	105	103.0	102.0	(83.4-123.4)
<u>Lung and Bronchus</u>									
Male	14	15.4	91.2	(49.8-152.9)					
Female	9	13.5	66.6	(30.4-126.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	21.5	69.6	(38.9-114.9)	Male	11	10.8	102.0	(50.8-182.5)
Female	11	7.8	140.6	(70.1-251.6)	Female	10	8.5	117.4	(56.2-215.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.7	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
Female	7	3.3	210.5	(84.3-433.8)	Female	3	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	0.7	nc	(nc-nc)	Male	6	10.4	57.5	(21.0-125.2)
Female	83	78.3	106.0	(84.4-131.4)	Female	16	9.9	161.9	(92.5-263.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.1	nc	(nc-nc)	Male	2	7.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	3.9	nc	(nc-nc)
Male	24	32.4	74.1	(47.4-110.2)	<u>Ovary</u>				
Female	33	32.8	100.7	(69.3-141.4)	Female	8	8.3	96.1	(41.4-189.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	5.3	nc	(nc-nc)	Male	6	6.1	97.8	(35.7-212.9)
Female	0	1.6	nc	(nc-nc)	Female	6	6.9	87.1	(31.8-189.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.3	nc	(nc-nc)	Male	88	85.3	103.1	(82.7-127.1)
Female	0	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	5.5	nc	(nc-nc)
Male	7	8.6	81.8	(32.8-168.7)	Female	1	3.5	nc	(nc-nc)
Female	10	5.6	179.7	(86.0-330.4)	<u>Testis</u>				
<u>Larynx</u>					Male	4	1.9	nc	(nc-nc)
Male	2	3.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.0	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
<u>Leukemia</u>					Female	3	6.2	nc	(nc-nc)
Male	7	6.4	109.6	(43.9-225.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	5.5	108.5	(39.6-236.2)	Female	20	16.0	125.2	(76.5-193.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.0	nc	(nc-nc)	Male	223	279.4	79.8	(69.7-91.0)
Female	0	1.6	nc	(nc-nc)	Female	271	264.1	102.6	(90.8-115.6)
<u>Lung and Bronchus</u>									
Male	19	40.3	47.2	(28.4-73.7)					
Female	28	36.4	77.0	(51.2-111.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lowell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	93	81.8	113.7	(91.8-139.3)	Male	19	47.7	39.8	(24.0-62.2)
Female	28	33.8	82.9	(55.1-119.9)	Female	18	43.0	41.8	(24.8-66.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	19	18.4	103.2	(62.1-161.2)	Male	12	12.0	99.7	(51.4-174.1)
Female	14	16.8	83.4	(45.5-139.9)	Female	11	11.0	99.9	(49.8-178.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	2.6	nc	(nc-nc)	Male	50	45.5	109.9	(81.5-144.8)
Female	291	346.8	83.9	(74.5-94.1)	Female	47	44.9	104.6	(76.9-139.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	25	16.4	152.3	(98.6-224.9)	Male	57	32.5	175.2	(132.7-226.9)
<u>Colon / Rectum</u>					Female	29	17.7	164.2	(109.9-235.8)
Male	124	125.1	99.1	(82.4-118.1)	<u>Ovary</u>				
Female	155	139.7	111.0	(94.2-129.9)	Female	35	37.3	93.9	(65.4-130.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	27	20.7	130.7	(86.1-190.2)	Male	18	23.6	76.4	(45.2-120.7)
Female	7	6.7	105.1	(42.1-216.5)	Female	32	29.5	108.6	(74.3-153.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	9	9.4	95.7	(43.7-181.6)	Male	292	333.4	87.6	(77.8-98.2)
Female	12	8.3	145.3	(75.0-253.8)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	17	21.1	80.5	(46.8-128.8)
Male	31	35.3	87.8	(59.7-124.7)	Female	14	14.9	94.2	(51.5-158.1)
Female	30	24.9	120.5	(81.3-172.1)	<u>Testis</u>				
<u>Larynx</u>					Male	7	18.1	38.7	(15.5-79.8)
Male	32	14.5	220.6	(150.9-311.4)	<u>Thyroid</u>				
Female	8	4.4	183.6	(79.1-361.8)	Male	4	10.7	nc	(nc-nc)
<u>Leukemia</u>					Female	34	36.4	93.3	(64.6-130.4)
Male	25	28.4	88.1	(57.0-130.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	38	26.1	145.5	(103.0-199.7)	Female	75	69.4	108.1	(85.0-135.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	21	16.4	128.2	(79.3-196.0)	Male	1134	1131.0	100.3	(94.5-106.3)
Female	10	6.9	145.9	(69.8-268.3)	Female	1166	1183.8	98.5	(92.9-104.3)
<u>Lung and Bronchus</u>									
Male	189	156.7	120.6	(104.1-139.1)					
Female	175	159.8	109.5	(93.9-127.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ludlow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	24.2	57.8	(31.6-97.0)	Male	8	13.1	61.0	(26.3-120.1)
Female	6	8.7	68.8	(25.1-149.8)	Female	5	10.1	49.5	(15.9-115.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	4.6	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
Female	5	3.9	129.4	(41.7-302.0)	Female	3	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	14	12.5	111.6	(61.0-187.3)
Female	93	88.6	104.9	(84.7-128.6)	Female	11	11.3	97.5	(48.6-174.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	3.8	131.7	(42.5-307.4)	Male	6	9.2	65.2	(23.8-141.9)
<u>Colon / Rectum</u>					Female	4	4.4	nc	(nc-nc)
Male	32	36.7	87.2	(59.7-123.1)	<u>Ovary</u>				
Female	34	35.4	95.9	(66.4-134.0)	Female	10	9.4	106.9	(51.2-196.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	6.0	82.8	(26.7-193.2)	Male	5	6.9	72.2	(23.3-168.5)
Female	0	1.7	nc	(nc-nc)	Female	6	7.6	79.3	(29.0-172.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.1	nc	(nc-nc)	Male	99	98.6	100.4	(81.6-122.2)
Female	0	1.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	6.2	97.5	(35.6-212.3)
Male	12	10.1	119.1	(61.5-208.1)	Female	0	3.7	nc	(nc-nc)
Female	2	6.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	5	3.7	135.0	(43.5-315.0)
Male	5	4.2	118.1	(38.1-275.6)	<u>Thyroid</u>				
Female	0	1.1	nc	(nc-nc)	Male	5	2.7	186.8	(60.2-435.9)
<u>Leukemia</u>					Female	6	7.8	76.6	(28.0-166.7)
Male	11	7.6	145.4	(72.5-260.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	6.1	nc	(nc-nc)	Female	25	18.0	138.7	(89.7-204.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	4.7	nc	(nc-nc)	Male	299	325.5	91.9	(81.8-102.9)
Female	1	1.7	nc	(nc-nc)	Female	264	298.6	88.4	(78.1-99.7)
<u>Lung and Bronchus</u>									
Male	45	46.4	96.9	(70.7-129.6)					
Female	22	42.4	51.9	(32.5-78.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lunenburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	10.0	90.3	(41.2-171.4)	Male	4	5.6	nc	(nc-nc)
Female	2	3.2	nc	(nc-nc)	Female	3	4.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.0	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.3	nc	(nc-nc)
Female	39	37.8	103.1	(73.3-140.9)	Female	6	4.4	137.7	(50.3-299.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.7	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.8	nc	(nc-nc)
Male	16	15.3	104.3	(59.6-169.3)	<u>Ovary</u>				
Female	16	13.0	122.8	(70.1-199.4)	Female	2	3.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	2.6	194.6	(62.7-454.2)	Male	2	2.9	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	4	2.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	39	41.4	94.2	(67.0-128.8)
Female	2	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.6	nc	(nc-nc)
Male	7	4.4	160.7	(64.4-331.1)	Female	0	1.3	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.4	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	1	3.7	nc	(nc-nc)
Male	5	3.2	156.4	(50.4-365.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	2.4	nc	(nc-nc)	Female	3	7.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	2.1	nc	(nc-nc)	Male	130	136.8	95.0	(79.4-112.8)
Female	0	0.7	nc	(nc-nc)	Female	112	120.0	93.3	(76.8-112.3)
<u>Lung and Bronchus</u>									
Male	22	19.3	114.1	(71.5-172.7)					
Female	16	16.0	100.1	(57.2-162.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lynn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	102	84.2	121.1	(98.7-147.0)	Male	40	45.7	87.5	(62.5-119.1)
Female	37	32.8	112.9	(79.5-155.7)	Female	25	39.8	62.8	(40.7-92.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	18	16.8	107.0	(63.4-169.1)	Male	15	12.2	122.8	(68.7-202.6)
Female	19	15.5	122.6	(73.8-191.5)	Female	14	10.7	131.2	(71.6-220.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	5	2.6	190.5	(61.4-444.5)	Male	55	44.1	124.8	(94.0-162.5)
Female	306	333.0	91.9	(81.9-102.8)	Female	44	42.8	102.7	(74.6-137.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	19	15.1	126.2	(75.9-197.1)	Male	40	31.5	127.1	(90.8-173.1)
<u>Colon / Rectum</u>					Female	21	16.9	124.3	(76.9-190.0)
Male	144	127.5	113.0	(95.3-133.0)	<u>Ovary</u>				
Female	132	135.3	97.6	(81.7-115.7)	Female	23	35.6	64.7	(41.0-97.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	29	20.7	140.4	(94.0-201.6)	Male	27	24.0	112.5	(74.1-163.6)
Female	6	6.5	92.8	(33.9-201.9)	Female	37	28.6	129.3	(91.1-178.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	11	7.6	144.0	(71.8-257.6)	Male	283	330.5	85.6	(75.9-96.2)
Female	10	6.8	146.5	(70.1-269.4)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	34	21.6	157.5	(109.1-220.1)
Male	33	34.5	95.5	(65.7-134.2)	Female	15	14.3	104.7	(58.6-172.7)
Female	31	23.9	129.6	(88.0-184.0)	<u>Testis</u>				
<u>Larynx</u>					Male	15	13.9	107.6	(60.2-177.4)
Male	27	14.3	188.2	(124.0-273.8)	<u>Thyroid</u>				
Female	9	4.2	213.6	(97.4-405.4)	Male	9	9.4	95.4	(43.5-181.0)
<u>Leukemia</u>					Female	24	32.3	74.2	(47.6-110.5)
Male	36	27.4	131.3	(91.9-181.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	32	24.5	130.4	(89.2-184.2)	Female	62	67.0	92.6	(71.0-118.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	29	16.1	180.6	(121.0-259.4)	Male	1243	1120.2	111.0	(104.9-117.3)
Female	10	6.6	151.4	(72.5-278.5)	Female	1174	1132.7	103.6	(97.8-109.7)
<u>Lung and Bronchus</u>									
Male	207	158.5	130.6	(113.4-149.6)					
Female	196	155.1	126.4	(109.3-145.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lynnfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	16.7	83.9	(45.8-140.7)	Male	10	8.4	119.2	(57.1-219.3)
Female	9	5.3	170.0	(77.6-322.8)	Female	11	6.1	180.7	(90.1-323.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.8	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	5	8.1	61.6	(19.8-143.7)
Female	54	55.7	97.0	(72.8-126.5)	Female	10	6.8	146.5	(70.1-269.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.3	nc	(nc-nc)	Male	4	6.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	6	2.7	218.3	(79.7-475.2)
Male	31	25.1	123.3	(83.7-175.0)	<u>Ovary</u>				
Female	21	21.5	97.8	(60.5-149.5)	Female	6	5.8	103.0	(37.6-224.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	4.1	146.1	(53.3-317.9)	Male	4	4.8	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	3	4.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.0	nc	(nc-nc)	Male	77	67.1	114.8	(90.6-143.5)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	4.2	118.3	(38.1-276.1)
Male	5	6.7	74.7	(24.1-174.3)	Female	1	2.2	nc	(nc-nc)
Female	2	3.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.6	nc	(nc-nc)
Male	1	2.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.7	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	2	4.6	nc	(nc-nc)
Male	7	5.0	141.2	(56.6-291.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	3.7	nc	(nc-nc)	Female	9	11.5	78.1	(35.6-148.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.1	nc	(nc-nc)	Male	223	218.3	102.2	(89.2-116.5)
Female	2	1.1	nc	(nc-nc)	Female	181	183.7	98.5	(84.7-114.0)
<u>Lung and Bronchus</u>									
Male	26	31.7	82.1	(53.6-120.3)					
Female	18	25.9	69.5	(41.2-109.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Malden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	56	56.6	98.9	(74.7-128.4)	Male	17	30.9	55.0	(32.0-88.1)
Female	30	22.5	133.4	(90.0-190.4)	Female	28	27.4	102.3	(68.0-147.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	11.0	82.2	(37.5-156.0)	Male	8	8.2	97.8	(42.1-192.8)
Female	8	10.2	78.1	(33.6-153.9)	Female	4	7.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.8	nc	(nc-nc)	Male	29	29.6	98.1	(65.7-140.9)
Female	214	225.8	94.8	(82.5-108.4)	Female	27	29.3	92.2	(60.7-134.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	12	10.3	116.2	(60.0-203.1)	Male	21	21.0	99.9	(61.8-152.7)
<u>Colon / Rectum</u>					Female	10	11.5	86.7	(41.5-159.5)
Male	101	85.5	118.2	(96.3-143.6)	<u>Ovary</u>				
Female	101	92.9	108.7	(88.5-132.1)	Female	22	24.2	91.0	(57.0-137.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	14	13.9	100.6	(54.9-168.8)	Male	17	16.1	105.8	(61.6-169.5)
Female	6	4.4	134.9	(49.3-293.6)	Female	14	19.6	71.3	(38.9-119.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	5.2	nc	(nc-nc)	Male	192	225.9	85.0	(73.4-97.9)
Female	4	4.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	15	14.5	103.6	(57.9-170.8)
Male	21	23.1	90.8	(56.2-138.8)	Female	22	9.9	222.2	(139.2-336.5)
Female	15	16.2	92.5	(51.7-152.5)	<u>Testis</u>				
<u>Larynx</u>					Male	2	10.1	nc	(nc-nc)
Male	7	9.7	72.3	(29.0-148.9)	<u>Thyroid</u>				
Female	4	2.9	nc	(nc-nc)	Male	10	6.5	154.3	(73.9-283.8)
<u>Leukemia</u>					Female	32	22.3	143.5	(98.1-202.6)
Male	9	18.0	50.0	(22.8-95.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	24	16.4	146.7	(94.0-218.3)	Female	31	45.6	68.1	(46.2-96.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	13	10.7	121.3	(64.5-207.4)	Male	723	756.3	95.6	(88.8-102.8)
Female	7	4.5	154.0	(61.7-317.3)	Female	786	772.2	101.8	(94.8-109.2)
<u>Lung and Bronchus</u>									
Male	130	106.9	121.7	(101.6-144.5)					
Female	106	106.0	100.0	(81.9-121.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Manchester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	7.0	71.4	(23.0-166.7)	Male	3	3.7	nc	(nc-nc)
Female	6	2.4	245.3	(89.6-534.0)	Female	4	2.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	1.2	401.6	(129.4-937.3)	Male	0	1.0	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
Female	38	26.3	144.6	(102.3-198.5)	Female	4	3.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.1	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	1.3	nc	(nc-nc)
Male	9	10.7	84.4	(38.5-160.2)	<u>Ovary</u>				
Female	2	9.9	nc	(nc-nc)	Female	4	2.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.8	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	28	29.8	94.1	(62.5-136.0)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.8	nc	(nc-nc)
Male	0	2.9	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.2	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.7	nc	(nc-nc)	Female	3	5.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.4	nc	(nc-nc)	Male	76	94.5	80.4	(63.3-100.6)
Female	0	0.5	nc	(nc-nc)	Female	93	85.8	108.4	(87.5-132.8)
<u>Lung and Bronchus</u>									
Male	7	13.6	51.6	(20.7-106.3)					
Female	8	11.9	67.3	(29.0-132.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mansfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	13.4	104.2	(56.9-174.9)	Male	16	9.2	173.8	(99.3-282.3)
Female	7	4.7	150.5	(60.3-310.2)	Female	12	8.2	146.5	(75.6-255.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	3.7	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	7	8.4	82.9	(33.2-170.8)
Female	57	62.3	91.5	(69.3-118.6)	Female	3	6.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	3.6	140.6	(45.3-328.2)	Male	6	6.3	94.7	(34.6-206.1)
<u>Colon / Rectum</u>					Female	5	2.9	174.1	(56.1-406.4)
Male	26	21.3	122.0	(79.7-178.8)	<u>Ovary</u>				
Female	21	19.1	109.8	(67.9-167.8)	Female	9	6.4	141.3	(64.5-268.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	3.6	331.3	(171.0-578.8)	Male	2	4.0	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	4	3.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.8	nc	(nc-nc)	Male	48	56.1	85.6	(63.1-113.5)
Female	5	1.5	326.5	(105.2-762.0)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	3.6	nc	(nc-nc)
Male	5	6.6	75.6	(24.4-176.5)	Female	2	2.0	nc	(nc-nc)
Female	4	3.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	5	3.8	131.4	(42.4-306.7)
Male	1	2.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	9	8.1	111.2	(50.7-211.0)
Male	4	5.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	4.2	nc	(nc-nc)	Female	11	11.8	93.1	(46.4-166.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.1	nc	(nc-nc)	Male	190	197.6	96.2	(83.0-110.9)
Female	3	1.0	nc	(nc-nc)	Female	207	192.8	107.4	(93.2-123.0)
<u>Lung and Bronchus</u>									
Male	20	26.1	76.6	(46.8-118.3)					
Female	26	22.9	113.6	(74.2-166.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marblehead

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	33	26.0	126.9	(87.3-178.2)	Male	41	13.6	300.9	(215.9-408.3)
Female	12	9.0	132.7	(68.5-231.9)	Female	20	11.0	182.1	(111.2-281.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	4.7	171.4	(73.8-337.7)	Male	2	3.8	nc	(nc-nc)
Female	1	4.1	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	16	13.0	122.9	(70.2-199.5)
Female	126	97.8	128.9	(107.4-153.4)	Female	14	11.8	118.7	(64.8-199.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.2	nc	(nc-nc)	Male	7	9.9	70.4	(28.2-145.0)
<u>Colon / Rectum</u>					Female	6	4.8	125.5	(45.8-273.1)
Male	48	39.5	121.6	(89.6-161.2)	<u>Ovary</u>				
Female	42	37.2	113.0	(81.5-152.8)	Female	7	10.2	68.5	(27.4-141.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	6.5	nc	(nc-nc)	Male	9	7.5	120.1	(54.8-228.1)
Female	1	1.8	nc	(nc-nc)	Female	9	7.8	115.0	(52.5-218.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.7	nc	(nc-nc)	Male	126	106.4	118.4	(98.6-141.0)
Female	0	1.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	6.6	nc	(nc-nc)
Male	7	10.8	65.0	(26.1-134.0)	Female	3	3.9	nc	(nc-nc)
Female	4	6.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.8	nc	(nc-nc)
Male	4	4.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.2	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
<u>Leukemia</u>					Female	7	8.6	81.0	(32.4-166.8)
Male	11	7.9	139.3	(69.4-249.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	6.5	nc	(nc-nc)	Female	14	19.9	70.3	(38.4-118.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	5.0	nc	(nc-nc)	Male	395	346.2	114.1	(103.1-125.9)
Female	0	1.8	nc	(nc-nc)	Female	339	319.8	106.0	(95.0-117.9)
<u>Lung and Bronchus</u>									
Male	36	49.6	72.6	(50.9-100.6)					
Female	38	43.6	87.1	(61.7-119.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marion

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	7.2	83.0	(30.3-180.7)	Male	1	3.7	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.2	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
Female	27	25.3	106.7	(70.3-155.2)	Female	3	3.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	0	2.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.3	nc	(nc-nc)
Male	8	10.9	73.3	(31.6-144.5)	<u>Ovary</u>				
Female	10	10.0	99.5	(47.7-183.1)	Female	2	2.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.8	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.5	nc	(nc-nc)	Male	29	29.0	99.9	(66.9-143.5)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.8	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.7	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.3	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.1	nc	(nc-nc)
Male	0	2.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	1.7	nc	(nc-nc)	Female	10	5.2	190.8	(91.4-351.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.4	nc	(nc-nc)	Male	84	94.7	88.7	(70.8-109.9)
Female	0	0.5	nc	(nc-nc)	Female	87	84.2	103.3	(82.7-127.4)
<u>Lung and Bronchus</u>									
Male	13	13.7	95.0	(50.6-162.5)					
Female	9	11.7	76.6	(35.0-145.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	30	32.3	92.8	(62.6-132.5)	Male	13	18.9	68.7	(36.6-117.5)
Female	11	12.4	89.0	(44.4-159.3)	Female	12	16.2	73.9	(38.2-129.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	6.9	115.4	(49.7-227.5)	Male	4	4.8	nc	(nc-nc)
Female	5	6.1	82.2	(26.5-191.8)	Female	5	4.0	124.7	(40.2-290.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.1	nc	(nc-nc)	Male	14	17.8	78.6	(42.9-131.9)
Female	133	132.9	100.1	(83.8-118.6)	Female	16	16.4	97.3	(55.6-158.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	6.4	nc	(nc-nc)	Male	17	13.1	129.7	(75.5-207.6)
<u>Colon / Rectum</u>					Female	10	6.6	151.4	(72.5-278.5)
Male	53	49.7	106.7	(79.9-139.5)	<u>Ovary</u>				
Female	44	51.0	86.4	(62.7-115.9)	Female	15	14.0	106.8	(59.8-176.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	8.2	60.6	(19.5-141.5)	Male	5	9.4	53.3	(17.2-124.4)
Female	4	2.4	nc	(nc-nc)	Female	12	10.7	112.2	(57.9-196.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	3.3	nc	(nc-nc)	Male	128	132.2	96.8	(80.8-115.1)
Female	2	2.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	8.4	71.3	(26.0-155.2)
Male	15	14.1	106.6	(59.6-175.8)	Female	8	5.4	147.1	(63.4-289.9)
Female	7	9.2	76.1	(30.5-156.8)	<u>Testis</u>				
<u>Larynx</u>					Male	6	6.5	92.4	(33.8-201.2)
Male	5	5.8	86.3	(27.8-201.3)	<u>Thyroid</u>				
Female	1	1.6	nc	(nc-nc)	Male	5	4.2	119.7	(38.6-279.2)
<u>Leukemia</u>					Female	21	13.8	151.9	(94.0-232.2)
Male	9	10.8	83.3	(38.0-158.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	9.4	117.3	(58.5-209.9)	Female	21	26.6	78.9	(48.8-120.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	6.5	91.8	(33.5-199.7)	Male	427	445.9	95.8	(86.9-105.3)
Female	3	2.5	nc	(nc-nc)	Female	424	441.5	96.0	(87.1-105.6)
<u>Lung and Bronchus</u>									
Male	68	61.7	110.1	(85.5-139.6)					
Female	50	58.5	85.5	(63.5-112.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marshfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	30	20.8	144.3	(97.3-206.0)	Male	17	12.7	134.0	(78.0-214.6)
Female	11	7.2	152.6	(76.1-273.1)	Female	16	10.7	149.6	(85.4-242.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	4.7	254.7	(131.5-445.0)	Male	7	3.2	222.1	(89.0-457.7)
Female	2	4.0	nc	(nc-nc)	Female	4	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	10	11.7	85.1	(40.8-156.6)
Female	93	90.5	102.8	(83.0-126.0)	Female	6	10.0	59.7	(21.8-130.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	4.4	nc	(nc-nc)	Male	10	9.3	107.1	(51.3-197.0)
<u>Colon / Rectum</u>					Female	3	4.2	nc	(nc-nc)
Male	40	32.5	123.1	(87.9-167.6)	<u>Ovary</u>				
Female	32	28.9	110.8	(75.7-156.4)	Female	12	9.3	129.5	(66.9-226.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	5.6	nc	(nc-nc)	Male	8	6.2	129.2	(55.6-254.6)
Female	1	1.4	nc	(nc-nc)	Female	5	6.0	82.7	(26.6-193.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.0	nc	(nc-nc)	Male	121	91.3	132.5	(109.9-158.3)
Female	1	1.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	5.4	110.6	(40.4-240.7)
Male	9	9.7	92.5	(42.2-175.7)	Female	3	2.9	nc	(nc-nc)
Female	3	5.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	3.7	nc	(nc-nc)
Male	3	4.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.1	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
<u>Leukemia</u>					Female	13	9.5	137.5	(73.2-235.2)
Male	8	7.1	112.5	(48.4-221.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	5.7	141.6	(61.0-279.0)	Female	29	18.4	158.0	(105.8-226.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	4.6	nc	(nc-nc)	Male	376	298.6	125.9	(113.5-139.3)
Female	1	1.5	nc	(nc-nc)	Female	298	281.0	106.1	(94.4-118.8)
<u>Lung and Bronchus</u>									
Male	52	40.9	127.0	(94.8-166.6)					
Female	41	36.4	112.7	(80.9-152.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mashpee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	25	17.8	140.6	(91.0-207.6)	Male	14	8.7	161.0	(87.9-270.1)
Female	6	5.8	103.5	(37.8-225.3)	Female	7	6.7	104.7	(42.0-215.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.9	nc	(nc-nc)	Male	6	2.5	237.8	(86.8-517.5)
Female	4	2.6	nc	(nc-nc)	Female	4	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	0.5	nc	(nc-nc)	Male	11	8.5	129.8	(64.7-232.2)
Female	98	59.3	165.2	(134.1-201.4)	Female	7	7.4	94.3	(37.8-194.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.5	nc	(nc-nc)	Male	6	6.2	97.5	(35.6-212.3)
<u>Colon / Rectum</u>					Female	3	3.0	nc	(nc-nc)
Male	36	26.5	136.1	(95.3-188.4)	<u>Ovary</u>				
Female	26	23.0	113.1	(73.8-165.7)	Female	5	6.2	80.1	(25.8-186.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	4.3	nc	(nc-nc)	Male	6	5.0	120.0	(43.8-261.2)
Female	4	1.1	nc	(nc-nc)	Female	2	4.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.1	nc	(nc-nc)	Male	108	72.2	149.5	(122.6-180.5)
Female	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	4.4	113.1	(36.5-264.0)
Male	9	7.0	129.0	(58.9-245.0)	Female	5	2.4	211.5	(68.2-493.7)
Female	9	4.3	210.4	(96.0-399.4)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.7	nc	(nc-nc)
Male	4	3.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.8	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<u>Leukemia</u>					Female	3	5.1	nc	(nc-nc)
Male	5	5.2	95.8	(30.9-223.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	4.0	174.9	(70.1-360.3)	Female	17	12.3	137.8	(80.3-220.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	3.2	156.2	(50.3-364.5)	Male	320	231.5	138.2	(123.5-154.2)
Female	0	1.1	nc	(nc-nc)	Female	248	198.3	125.1	(110.0-141.6)
<u>Lung and Bronchus</u>									
Male	49	34.0	144.1	(106.6-190.5)					
Female	28	28.5	98.2	(65.2-141.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mattapoisett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	8.3	59.9	(19.3-139.8)	Male	10	4.3	231.5	(110.8-425.8)
Female	3	2.9	nc	(nc-nc)	Female	8	3.4	238.3	(102.6-469.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.5	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	4.1	nc	(nc-nc)
Female	36	30.5	118.2	(82.8-163.6)	Female	2	3.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.3	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.5	nc	(nc-nc)
Male	19	12.6	150.7	(90.7-235.3)	<u>Ovary</u>				
Female	13	11.8	110.0	(58.5-188.1)	Female	3	3.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.1	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	30	34.6	86.6	(58.4-123.6)
Female	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.1	nc	(nc-nc)
Male	3	3.4	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.9	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.5	nc	(nc-nc)
Male	6	2.5	240.6	(87.9-523.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	2.0	nc	(nc-nc)	Female	8	6.3	127.1	(54.7-250.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.6	nc	(nc-nc)	Male	111	111.2	99.8	(82.1-120.2)
Female	0	0.6	nc	(nc-nc)	Female	106	100.6	105.4	(86.3-127.5)
<u>Lung and Bronchus</u>									
Male	10	16.0	62.6	(30.0-115.1)					
Female	15	14.0	107.2	(60.0-176.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Maynard

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	10.0	nc	(nc-nc)	Male	2	5.7	nc	(nc-nc)
Female	5	3.9	127.3	(41.0-297.1)	Female	5	5.1	98.1	(31.6-229.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.1	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.4	nc	(nc-nc)
Female	36	42.6	84.5	(59.2-117.0)	Female	12	5.2	230.0	(118.7-401.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.0	nc	(nc-nc)	Male	5	4.0	124.1	(40.0-289.7)
<u>Colon / Rectum</u>					Female	0	2.1	nc	(nc-nc)
Male	16	15.3	104.6	(59.7-169.8)	<u>Ovary</u>				
Female	11	16.1	68.1	(34.0-121.9)	Female	4	4.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.5	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	7	3.4	206.0	(82.5-424.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.9	nc	(nc-nc)	Male	31	40.6	76.3	(51.9-108.4)
Female	2	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.6	nc	(nc-nc)
Male	6	4.3	139.2	(50.8-302.9)	Female	4	1.7	nc	(nc-nc)
Female	5	2.9	170.0	(54.8-396.7)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.7	nc	(nc-nc)
Male	3	1.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	3	4.3	nc	(nc-nc)
Male	1	3.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	2.9	nc	(nc-nc)	Female	9	8.6	105.2	(48.0-199.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.0	nc	(nc-nc)	Male	120	136.2	88.1	(73.0-105.3)
Female	0	0.8	nc	(nc-nc)	Female	135	140.5	96.1	(80.6-113.7)
<u>Lung and Bronchus</u>									
Male	19	18.9	100.3	(60.3-156.6)					
Female	14	18.8	74.4	(40.6-124.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Medfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	10.3	116.9	(60.3-204.2)	Male	9	6.3	143.1	(65.3-271.7)
Female	1	3.5	nc	(nc-nc)	Female	8	5.1	156.0	(67.2-307.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.4	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	6	5.9	102.5	(37.4-223.2)
Female	52	44.3	117.3	(87.6-153.9)	Female	1	4.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.1	nc	(nc-nc)	Male	6	4.7	128.1	(46.8-278.7)
<u>Colon / Rectum</u>					Female	3	2.0	nc	(nc-nc)
Male	13	16.1	80.8	(43.0-138.2)	<u>Ovary</u>				
Female	19	14.3	133.2	(80.1-208.0)	Female	4	4.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.8	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	3.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.0	nc	(nc-nc)	Male	64	45.0	142.2	(109.5-181.6)
Female	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.7	nc	(nc-nc)
Male	2	4.9	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.7	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Leukemia</u>					Female	6	4.5	132.3	(48.3-288.0)
Male	4	3.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	2.8	176.5	(56.9-411.9)	Female	8	8.8	91.4	(39.3-180.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.3	nc	(nc-nc)	Male	157	147.7	106.3	(90.3-124.2)
Female	1	0.7	nc	(nc-nc)	Female	148	137.0	108.0	(91.3-126.9)
<u>Lung and Bronchus</u>									
Male	21	20.4	103.1	(63.8-157.6)					
Female	23	17.5	131.6	(83.4-197.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Medford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	65	67.0	97.0	(74.9-123.7)	Male	25	33.8	73.9	(47.8-109.1)
Female	34	26.9	126.3	(87.5-176.5)	Female	19	29.8	63.8	(38.4-99.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	11.6	69.1	(29.8-136.2)	Male	13	9.5	136.9	(72.8-234.1)
Female	9	11.3	79.5	(36.3-151.0)	Female	10	8.7	114.3	(54.7-210.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	2.0	nc	(nc-nc)	Male	26	33.0	78.8	(51.4-115.4)
Female	287	254.6	112.7	(100.1-126.6)	Female	42	34.2	123.0	(88.6-166.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	10.8	64.6	(25.9-133.0)	Male	27	22.9	117.8	(77.6-171.4)
<u>Colon / Rectum</u>					Female	15	13.2	113.4	(63.4-187.0)
Male	104	99.8	104.2	(85.2-126.3)	<u>Ovary</u>				
Female	110	111.8	98.4	(80.9-118.6)	Female	24	27.5	87.4	(56.0-130.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	15.9	81.7	(43.5-139.8)	Male	16	18.7	85.4	(48.8-138.7)
Female	7	5.3	131.4	(52.6-270.8)	Female	17	23.7	71.7	(41.7-114.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	7	5.2	134.0	(53.7-276.1)	Male	206	257.5	80.0	(69.5-91.7)
Female	5	4.8	103.7	(33.4-242.1)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	23	16.9	136.1	(86.3-204.3)
Male	19	25.8	73.6	(44.3-114.9)	Female	16	11.9	134.3	(76.7-218.1)
Female	15	18.8	79.7	(44.6-131.5)	<u>Testis</u>				
<u>Larynx</u>					Male	13	9.3	139.5	(74.2-238.5)
Male	14	10.9	127.9	(69.9-214.6)	<u>Thyroid</u>				
Female	4	3.3	nc	(nc-nc)	Male	6	6.5	92.0	(33.6-200.3)
<u>Leukemia</u>					Female	27	22.7	119.0	(78.4-173.1)
Male	22	20.2	108.9	(68.2-164.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	24	18.9	127.1	(81.4-189.1)	Female	68	51.5	132.0	(102.5-167.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	13	11.9	109.0	(58.0-186.4)	Male	826	862.6	95.8	(89.3-102.5)
Female	7	5.4	130.0	(52.1-267.9)	Female	929	889.4	104.5	(97.8-111.4)
<u>Lung and Bronchus</u>									
Male	145	125.1	115.9	(97.8-136.4)					
Female	123	125.4	98.1	(81.5-117.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Medway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	9.3	162.0	(90.6-267.2)	Male	9	5.8	155.2	(70.8-294.7)
Female	6	3.5	172.7	(63.1-376.0)	Female	7	5.1	136.9	(54.9-282.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.2	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	4	5.4	nc	(nc-nc)
Female	41	41.8	98.1	(70.4-133.1)	Female	4	4.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.1	nc	(nc-nc)	Male	5	4.1	121.3	(39.1-283.1)
<u>Colon / Rectum</u>					Female	2	2.0	nc	(nc-nc)
Male	18	14.5	124.3	(73.7-196.5)	<u>Ovary</u>				
Female	17	14.3	118.9	(69.2-190.4)	Female	5	4.3	115.7	(37.3-270.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.5	nc	(nc-nc)	Male	5	2.7	182.3	(58.8-425.5)
Female	2	0.7	nc	(nc-nc)	Female	0	3.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.0	nc	(nc-nc)	Male	49	39.3	124.7	(92.3-164.9)
Female	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.4	nc	(nc-nc)
Male	5	4.3	115.2	(37.1-268.8)	Female	1	1.5	nc	(nc-nc)
Female	1	2.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.9	nc	(nc-nc)
Male	1	1.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	6	4.6	129.7	(47.4-282.3)
Male	2	3.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.9	nc	(nc-nc)	Female	11	8.1	135.7	(67.7-242.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.1	nc	(nc-nc)	Male	153	132.5	115.5	(97.9-135.3)
Female	0	0.7	nc	(nc-nc)	Female	138	132.8	103.9	(87.3-122.8)
<u>Lung and Bronchus</u>									
Male	18	18.1	99.4	(58.9-157.1)					
Female	19	16.8	113.1	(68.1-176.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Melrose

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	35	31.7	110.5	(76.9-153.6)	Male	19	16.6	114.4	(68.9-178.7)
Female	15	12.9	116.6	(65.2-192.3)	Female	23	14.6	157.9	(100.1-237.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.7	105.0	(38.3-228.5)	Male	6	4.6	131.5	(48.0-286.2)
Female	8	5.5	144.5	(62.2-284.7)	Female	3	4.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.0	nc	(nc-nc)	Male	22	16.0	137.8	(86.4-208.7)
Female	133	126.1	105.4	(88.3-125.0)	Female	10	16.4	61.1	(29.2-112.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	5.4	nc	(nc-nc)	Male	8	11.6	68.9	(29.7-135.8)
<u>Colon / Rectum</u>					Female	5	6.4	77.7	(25.0-181.3)
Male	57	47.8	119.3	(90.4-154.6)	<u>Ovary</u>				
Female	57	53.8	106.0	(80.3-137.3)	Female	20	13.5	148.2	(90.5-229.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	7.7	90.6	(36.3-186.8)	Male	10	9.0	111.1	(53.2-204.3)
Female	3	2.6	nc	(nc-nc)	Female	9	11.4	79.2	(36.2-150.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	2.4	254.6	(93.0-554.2)	Male	160	123.8	129.3	(110.0-150.9)
Female	4	2.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	8.1	86.3	(34.6-177.9)
Male	15	12.7	118.1	(66.1-194.8)	Female	5	5.8	86.8	(28.0-202.5)
Female	11	9.1	121.0	(60.3-216.5)	<u>Testis</u>				
<u>Larynx</u>					Male	3	4.2	nc	(nc-nc)
Male	4	5.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.6	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
<u>Leukemia</u>					Female	9	11.2	80.7	(36.8-153.2)
Male	8	9.7	82.3	(35.4-162.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	9.2	nc	(nc-nc)	Female	19	25.4	74.9	(45.1-117.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	5.9	84.4	(27.2-196.9)	Male	464	414.4	112.0	(102.0-122.6)
Female	5	2.6	193.4	(62.3-451.3)	Female	435	432.5	100.6	(91.3-110.5)
<u>Lung and Bronchus</u>									
Male	52	59.1	88.0	(65.7-115.4)					
Female	58	59.6	97.3	(73.9-125.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	4.2	nc	(nc-nc)	Male	5	2.7	187.5	(60.4-437.5)
Female	3	1.4	nc	(nc-nc)	Female	5	2.2	231.5	(74.6-540.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.0	nc	(nc-nc)	Male	3	0.6	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	15	17.9	83.8	(46.9-138.3)	Female	4	2.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	0.9	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.8	nc	(nc-nc)
Male	8	6.6	120.5	(51.9-237.4)	<u>Ovary</u>				
Female	2	5.7	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.1	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	14	18.1	77.2	(42.2-129.6)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.1	nc	(nc-nc)
Male	0	2.0	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.8	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	3	2.0	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.1	nc	(nc-nc)	Female	1	3.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.9	nc	(nc-nc)	Male	65	60.8	107.0	(82.6-136.4)
Female	0	0.3	nc	(nc-nc)	Female	52	55.3	93.9	(70.2-123.2)
<u>Lung and Bronchus</u>									
Male	12	8.2	145.9	(75.3-254.9)					
Female	7	6.9	101.6	(40.7-209.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Merrimac

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	5.8	136.9	(59.0-269.8)	Male	3	3.3	nc	(nc-nc)
Female	4	1.9	nc	(nc-nc)	Female	0	2.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	31	23.2	133.4	(90.6-189.4)	Female	3	2.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.1	nc	(nc-nc)
Male	7	9.0	78.1	(31.3-160.8)	<u>Ovary</u>				
Female	11	7.7	142.1	(70.8-254.2)	Female	3	2.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	1.5	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	33	24.2	136.4	(93.9-191.5)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.5	nc	(nc-nc)
Male	1	2.5	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.9	nc	(nc-nc)
Male	4	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.4	nc	(nc-nc)
Male	5	1.9	260.2	(83.9-607.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	1.5	nc	(nc-nc)	Female	6	4.6	129.1	(47.1-281.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.2	nc	(nc-nc)	Male	86	80.3	107.1	(85.7-132.3)
Female	0	0.4	nc	(nc-nc)	Female	79	73.3	107.7	(85.3-134.2)
<u>Lung and Bronchus</u>									
Male	9	11.2	80.5	(36.7-152.8)					
Female	11	9.7	113.4	(56.6-203.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Methuen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	47	47.9	98.1	(72.1-130.4)	Male	21	25.1	83.6	(51.7-127.7)
Female	24	19.1	125.6	(80.4-186.9)	Female	14	21.7	64.5	(35.2-108.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	15	8.9	168.7	(94.3-278.2)	Male	12	6.9	174.1	(89.8-304.1)
Female	11	8.4	130.9	(65.3-234.3)	Female	12	6.2	192.1	(99.1-335.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	1.5	nc	(nc-nc)	Male	22	24.3	90.4	(56.6-136.9)
Female	177	187.0	94.6	(81.2-109.6)	Female	24	24.5	97.8	(62.6-145.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	8.1	74.1	(27.0-161.2)	Male	21	17.3	121.6	(75.2-185.8)
<u>Colon / Rectum</u>					Female	12	9.5	125.8	(64.9-219.7)
Male	86	72.1	119.2	(95.4-147.2)	<u>Ovary</u>				
Female	89	79.7	111.7	(89.7-137.5)	Female	18	20.0	89.9	(53.3-142.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	11.6	95.2	(47.4-170.3)	Male	17	13.6	125.3	(72.9-200.6)
Female	4	3.8	nc	(nc-nc)	Female	17	16.9	100.9	(58.7-161.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	7	3.8	184.1	(73.7-379.3)	Male	205	183.8	111.6	(96.8-127.9)
Female	6	3.4	178.3	(65.1-388.2)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	12	12.2	98.3	(50.8-171.8)
Male	26	19.1	135.8	(88.7-199.0)	Female	5	8.5	58.9	(19.0-137.5)
Female	8	13.6	58.7	(25.3-115.7)	<u>Testis</u>				
<u>Larynx</u>					Male	11	6.7	163.1	(81.3-291.8)
Male	4	8.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	4	2.4	nc	(nc-nc)	Male	6	5.0	120.9	(44.1-263.2)
<u>Leukemia</u>					Female	14	16.8	83.1	(45.4-139.5)
Male	8	15.0	53.4	(23.0-105.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	13	13.8	94.2	(50.1-161.2)	Female	42	37.4	112.4	(81.0-152.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	8.9	78.7	(31.5-162.2)	Male	668	624.3	107.0	(99.0-115.4)
Female	5	3.8	130.7	(42.1-305.0)	Female	660	643.5	102.6	(94.9-110.7)
<u>Lung and Bronchus</u>									
Male	83	89.6	92.6	(73.8-114.8)					
Female	100	89.4	111.9	(91.0-136.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Middleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	16.8	89.5	(50.1-147.6)	Male	7	10.0	69.9	(28.0-144.0)
Female	5	6.3	79.0	(25.5-184.4)	Female	5	8.6	57.9	(18.7-135.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.8	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	4	3.3	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	9	9.4	95.6	(43.6-181.5)
Female	73	71.0	102.9	(80.6-129.3)	Female	11	8.6	128.5	(64.0-229.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.4	nc	(nc-nc)	Male	4	7.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	3.5	nc	(nc-nc)
Male	37	26.1	141.9	(99.9-195.7)	<u>Ovary</u>				
Female	31	26.3	117.8	(80.0-167.2)	Female	12	7.5	161.0	(83.1-281.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	4.4	nc	(nc-nc)	Male	5	4.9	101.1	(32.6-235.8)
Female	1	1.3	nc	(nc-nc)	Female	5	5.5	91.0	(29.3-212.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.7	nc	(nc-nc)	Male	66	69.1	95.5	(73.8-121.5)
Female	2	1.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	4.4	159.2	(63.8-328.0)
Male	5	7.5	66.5	(21.4-155.2)	Female	2	2.8	nc	(nc-nc)
Female	10	4.8	208.1	(99.6-382.8)	<u>Testis</u>				
<u>Larynx</u>					Male	2	3.2	nc	(nc-nc)
Male	3	3.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
<u>Leukemia</u>					Female	9	7.5	120.2	(54.8-228.2)
Male	3	5.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	4.9	121.9	(44.5-265.4)	Female	17	14.0	121.1	(70.5-193.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.5	nc	(nc-nc)	Male	242	234.0	103.4	(90.8-117.3)
Female	0	1.3	nc	(nc-nc)	Female	259	231.9	111.7	(98.5-126.1)
<u>Lung and Bronchus</u>									
Male	45	32.2	139.9	(102.0-187.2)					
Female	40	30.0	133.3	(95.2-181.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Middlefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	2.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.6	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	2.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.2	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	7.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	5	6.3	79.1	(25.5-184.6)
<u>Lung and Bronchus</u>									
Male	2	1.0	nc	(nc-nc)					
Female	0	0.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Middleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	6.7	133.3	(60.8-253.2)	Male	5	4.3	117.4	(37.8-273.9)
Female	3	2.2	nc	(nc-nc)	Female	1	2.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.6	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	4.0	126.2	(40.7-294.6)
Female	34	25.2	134.9	(93.4-188.6)	Female	4	2.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.2	nc	(nc-nc)	Male	0	2.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.2	nc	(nc-nc)
Male	7	10.5	66.7	(26.7-137.4)	<u>Ovary</u>				
Female	10	8.7	115.3	(55.2-212.0)	Female	1	2.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.8	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	25	27.9	89.5	(57.9-132.1)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	1.8	nc	(nc-nc)
Male	2	3.1	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.7	nc	(nc-nc)
Male	3	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	4	2.5	nc	(nc-nc)
Male	4	2.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.6	nc	(nc-nc)	Female	3	5.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.4	nc	(nc-nc)	Male	97	95.9	101.2	(82.1-123.4)
Female	0	0.4	nc	(nc-nc)	Female	97	80.5	120.6	(97.8-147.1)
<u>Lung and Bronchus</u>									
Male	19	13.0	145.8	(87.7-227.7)					
Female	14	10.9	128.8	(70.3-216.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Milford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	31	26.1	118.9	(80.8-168.7)	Male	9	14.5	61.9	(28.2-117.4)
Female	5	10.2	48.9	(15.8-114.1)	Female	14	12.6	111.5	(60.9-187.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	5.3	133.0	(53.3-274.1)	Male	3	3.8	nc	(nc-nc)
Female	8	4.8	167.3	(72.0-329.6)	Female	4	3.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	16	13.9	115.5	(66.0-187.5)
Female	92	105.5	87.2	(70.3-107.0)	Female	17	13.4	127.0	(73.9-203.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.8	nc	(nc-nc)	Male	9	10.2	88.6	(40.4-168.3)
<u>Colon / Rectum</u>					Female	6	5.3	113.2	(41.3-246.3)
Male	36	39.8	90.5	(63.4-125.2)	<u>Ovary</u>				
Female	33	42.7	77.2	(53.1-108.4)	Female	11	11.2	98.0	(48.9-175.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	6.5	107.5	(43.1-221.5)	Male	6	7.5	79.9	(29.2-173.9)
Female	0	2.0	nc	(nc-nc)	Female	7	9.0	78.0	(31.3-160.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	2.3	nc	(nc-nc)	Male	99	103.7	95.5	(77.6-116.2)
Female	3	2.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	13	6.7	193.8	(103.1-331.4)
Male	9	11.0	81.8	(37.3-155.3)	Female	5	4.6	109.3	(35.2-255.0)
Female	4	7.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	4.3	nc	(nc-nc)
Male	4	4.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.3	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
<u>Leukemia</u>					Female	7	10.2	68.4	(27.4-141.0)
Male	5	8.5	58.9	(19.0-137.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	7.7	nc	(nc-nc)	Female	20	21.1	94.8	(57.9-146.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	9	5.1	175.5	(80.1-333.1)	Male	334	351.0	95.2	(85.2-105.9)
Female	4	2.1	nc	(nc-nc)	Female	329	356.0	92.4	(82.7-103.0)
<u>Lung and Bronchus</u>									
Male	51	49.4	103.2	(76.8-135.6)					
Female	54	47.8	113.0	(84.8-147.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Millbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	14.8	114.7	(66.8-183.6)	Male	5	7.8	64.2	(20.7-149.8)
Female	3	5.8	nc	(nc-nc)	Female	3	6.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.7	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
Female	0	2.5	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	4	7.5	nc	(nc-nc)
Female	56	57.1	98.1	(74.1-127.4)	Female	10	7.4	135.0	(64.6-248.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.4	nc	(nc-nc)	Male	7	5.5	127.6	(51.1-262.9)
<u>Colon / Rectum</u>					Female	2	2.9	nc	(nc-nc)
Male	14	22.4	62.5	(34.1-104.9)	<u>Ovary</u>				
Female	18	24.1	74.7	(44.3-118.1)	Female	7	6.1	114.6	(45.9-236.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.6	137.1	(44.2-320.0)	Male	2	4.2	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	7	5.1	137.3	(55.0-282.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.1	nc	(nc-nc)	Male	56	58.8	95.2	(71.9-123.6)
Female	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.8	nc	(nc-nc)
Male	3	6.0	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
Female	6	4.1	145.2	(53.0-316.0)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.0	nc	(nc-nc)
Male	6	2.5	236.2	(86.3-514.1)	<u>Thyroid</u>				
Female	1	0.7	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	1	5.0	nc	(nc-nc)
Male	3	4.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	4.1	nc	(nc-nc)	Female	19	11.6	163.9	(98.6-255.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.8	nc	(nc-nc)	Male	177	195.5	90.6	(77.7-104.9)
Female	3	1.2	nc	(nc-nc)	Female	197	195.6	100.7	(87.1-115.8)
<u>Lung and Bronchus</u>									
Male	37	27.9	132.8	(93.5-183.0)					
Female	39	27.2	143.4	(102.0-196.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Millis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	6.4	187.5	(96.8-327.5)	Male	5	4.0	124.9	(40.2-291.5)
Female	3	2.3	nc	(nc-nc)	Female	4	3.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.5	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.2	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
Female	30	28.8	104.2	(70.3-148.7)	Female	3	3.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.4	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.3	nc	(nc-nc)
Male	9	10.0	89.6	(40.9-170.1)	<u>Ovary</u>				
Female	7	9.0	77.4	(31.0-159.5)	Female	2	2.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.7	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	35	28.4	123.0	(85.7-171.1)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.7	nc	(nc-nc)
Male	4	3.1	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	1.3	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	1	3.1	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.8	nc	(nc-nc)	Female	4	5.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.4	nc	(nc-nc)	Male	110	93.1	118.2	(97.1-142.5)
Female	0	0.5	nc	(nc-nc)	Female	91	89.2	102.0	(82.2-125.3)
<u>Lung and Bronchus</u>									
Male	18	12.8	141.2	(83.6-223.1)					
Female	18	11.5	156.5	(92.7-247.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Millville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	1.8	338.5	(123.6-736.8)	Male	2	1.2	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	3	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.5	nc	(nc-nc)	Male	2	0.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	9	8.1	110.9	(50.6-210.6)	Female	0	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.4	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	5	2.8	179.8	(57.9-419.6)	<u>Ovary</u>				
Female	3	2.7	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	7.5	92.8	(37.2-191.2)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	2	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.0	nc	(nc-nc)
Male	2	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.6	nc	(nc-nc)	Female	4	1.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	38	25.8	147.1	(104.1-202.0)
Female	0	0.1	nc	(nc-nc)	Female	31	26.0	119.4	(81.1-169.5)
<u>Lung and Bronchus</u>									
Male	7	3.5	200.4	(80.3-412.9)					
Female	4	3.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Milton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	30.6	68.6	(42.4-104.8)	Male	29	15.7	184.3	(123.4-264.7)
Female	18	12.1	148.7	(88.1-235.0)	Female	22	13.5	163.4	(102.4-247.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	5.5	nc	(nc-nc)	Male	4	4.4	nc	(nc-nc)
Female	5	5.2	95.6	(30.8-223.1)	Female	3	4.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	18	15.3	118.0	(69.9-186.5)
Female	116	119.1	97.4	(80.5-116.9)	Female	21	15.4	136.1	(84.2-208.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	5.0	100.4	(32.4-234.3)	Male	12	11.0	108.8	(56.2-190.1)
<u>Colon / Rectum</u>					Female	5	6.1	82.6	(26.6-192.8)
Male	46	46.1	99.9	(73.1-133.2)	<u>Ovary</u>				
Female	64	50.9	125.8	(96.9-160.7)	Female	13	12.7	102.1	(54.3-174.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	7.4	nc	(nc-nc)	Male	8	8.7	92.3	(39.7-181.8)
Female	2	2.4	nc	(nc-nc)	Female	12	10.7	112.0	(57.8-195.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.2	nc	(nc-nc)	Male	130	117.7	110.4	(92.2-131.1)
Female	1	2.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	7.8	76.8	(28.0-167.1)
Male	9	12.1	74.3	(33.9-141.0)	Female	3	5.5	nc	(nc-nc)
Female	7	8.6	81.6	(32.7-168.1)	<u>Testis</u>				
<u>Larynx</u>					Male	2	3.6	nc	(nc-nc)
Male	5	5.1	98.2	(31.6-229.1)	<u>Thyroid</u>				
Female	0	1.5	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
<u>Leukemia</u>					Female	9	10.2	88.3	(40.3-167.6)
Male	11	9.4	117.0	(58.3-209.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	8.7	68.9	(25.2-150.0)	Female	21	23.7	88.5	(54.8-135.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	5.7	87.7	(28.3-204.6)	Male	364	396.6	91.8	(82.6-101.7)
Female	2	2.4	nc	(nc-nc)	Female	421	407.2	103.4	(93.8-113.8)
<u>Lung and Bronchus</u>									
Male	29	57.0	50.9	(34.1-73.0)					
Female	55	56.1	98.1	(73.9-127.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Monroe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.0	nc	(nc-nc)
Male	1	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	0	0.2	nc	(nc-nc)					
Female	0	0.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Monson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	8.0	124.4	(59.5-228.7)	Male	8	4.8	168.0	(72.3-331.0)
Female	6	2.8	213.4	(77.9-464.6)	Female	0	3.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.7	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	4.4	nc	(nc-nc)
Female	25	32.8	76.3	(49.4-112.6)	Female	5	3.8	130.9	(42.2-305.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.5	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.6	nc	(nc-nc)
Male	9	12.5	72.2	(32.9-137.0)	<u>Ovary</u>				
Female	10	11.4	87.5	(41.9-160.9)	Female	2	3.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.1	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.8	nc	(nc-nc)	Male	26	34.3	75.8	(49.5-111.0)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.1	nc	(nc-nc)
Male	1	3.7	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
Female	4	2.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.3	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	5	3.3	152.3	(49.1-355.5)
Male	1	2.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.1	nc	(nc-nc)	Female	4	6.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.7	nc	(nc-nc)	Male	94	113.1	83.1	(67.2-101.7)
Female	1	0.6	nc	(nc-nc)	Female	96	104.7	91.7	(74.3-112.0)
<u>Lung and Bronchus</u>									
Male	20	15.7	127.1	(77.6-196.3)					
Female	17	13.8	122.8	(71.5-196.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Montague

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	9.8	51.2	(16.5-119.4)	Male	6	5.1	117.2	(42.8-255.1)
Female	4	3.9	nc	(nc-nc)	Female	1	4.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.8	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	3	1.7	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	9	4.9	181.9	(83.0-345.3)
Female	30	38.1	78.8	(53.2-112.5)	Female	4	5.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.6	nc	(nc-nc)	Male	7	3.6	196.2	(78.6-404.2)
<u>Colon / Rectum</u>					Female	3	1.9	nc	(nc-nc)
Male	13	14.8	88.1	(46.9-150.7)	<u>Ovary</u>				
Female	9	16.0	56.4	(25.7-107.0)	Female	3	4.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.4	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	3	3.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	39	38.1	102.3	(72.7-139.8)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.5	nc	(nc-nc)
Male	4	3.9	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
Female	1	2.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.3	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.5	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	3	3.3	nc	(nc-nc)
Male	4	3.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.8	nc	(nc-nc)	Female	6	7.7	78.0	(28.5-169.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.8	nc	(nc-nc)	Male	130	128.1	101.5	(84.8-120.5)
Female	0	0.8	nc	(nc-nc)	Female	98	130.5	75.1	(61.0-91.5)
<u>Lung and Bronchus</u>									
Male	19	18.5	102.7	(61.8-160.3)					
Female	12	18.6	64.6	(33.3-112.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Monterey

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.4	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	4.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.4	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	7	6.0	117.5	(47.1-242.2)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.4	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	17	18.7	90.9	(52.9-145.6)
Female	0	0.1	nc	(nc-nc)	Female	7	14.0	50.0	(20.0-103.0)
<u>Lung and Bronchus</u>									
Male	2	2.7	nc	(nc-nc)					
Female	2	2.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Montgomery

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	5	2.8	178.4	(57.5-416.3)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.1	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.9	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.1	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.3	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.2	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.2	nc	(nc-nc)	Male	13	10.8	120.0	(63.8-205.3)
Female	0	0.0	nc	(nc-nc)	Female	13	8.6	151.5	(80.6-259.1)
<u>Lung and Bronchus</u>									
Male	2	1.5	nc	(nc-nc)					
Female	1	1.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mount Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.0	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.1	nc	(nc-nc)
Male	1	0.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.0	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	0	0.5	nc	(nc-nc)					
Female	0	0.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Nahant

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.7	87.1	(28.1-203.2)	Male	4	2.8	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	0.9	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
Female	19	19.2	99.0	(59.6-154.7)	Female	0	2.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.8	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.0	nc	(nc-nc)
Male	12	8.6	139.7	(72.1-244.0)	<u>Ovary</u>				
Female	0	8.0	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.4	nc	(nc-nc)	Male	3	1.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	26	21.8	119.2	(77.9-174.7)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.5	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.5	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	3	1.6	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.3	nc	(nc-nc)	Female	1	3.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.0	nc	(nc-nc)	Male	83	72.8	114.0	(90.8-141.3)
Female	0	0.4	nc	(nc-nc)	Female	59	64.6	91.3	(69.5-117.8)
<u>Lung and Bronchus</u>									
Male	8	10.6	75.7	(32.6-149.2)					
Female	11	9.0	122.7	(61.2-219.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Nantucket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	8.5	130.0	(64.8-232.6)	Male	10	5.2	193.3	(92.5-355.5)
Female	5	2.9	170.0	(54.8-396.7)	Female	12	4.1	290.6	(150.0-507.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.9	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	4.8	nc	(nc-nc)
Female	46	33.3	138.3	(101.2-184.4)	Female	4	4.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.7	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.6	nc	(nc-nc)
Male	12	13.1	91.4	(47.2-159.7)	<u>Ovary</u>				
Female	13	12.0	108.7	(57.8-185.9)	Female	3	3.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.2	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	4	2.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.9	nc	(nc-nc)	Male	56	35.2	158.9	(120.0-206.4)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	2.2	nc	(nc-nc)
Male	1	3.8	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.9	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	4	3.7	nc	(nc-nc)
Male	1	2.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.2	nc	(nc-nc)	Female	1	6.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.8	nc	(nc-nc)	Male	128	119.0	107.5	(89.7-127.9)
Female	1	0.6	nc	(nc-nc)	Female	128	108.3	118.2	(98.6-140.6)
<u>Lung and Bronchus</u>									
Male	13	16.4	79.2	(42.2-135.5)					
Female	14	14.2	98.4	(53.7-165.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Natick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	34	34.1	99.6	(69.0-139.2)	Male	34	18.5	183.3	(126.9-256.2)
Female	15	13.3	112.7	(63.0-185.8)	Female	15	16.3	92.1	(51.5-151.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	6.5	137.4	(62.7-260.9)	Male	5	5.0	100.8	(32.5-235.2)
Female	8	6.1	130.6	(56.2-257.3)	Female	5	4.3	115.1	(37.1-268.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.1	nc	(nc-nc)	Male	17	17.7	96.3	(56.0-154.1)
Female	167	138.3	120.8	(103.1-140.5)	Female	19	17.4	109.4	(65.8-170.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	6.3	nc	(nc-nc)	Male	15	13.0	115.6	(64.6-190.6)
<u>Colon / Rectum</u>					Female	10	6.9	144.6	(69.2-265.9)
Male	63	51.7	121.9	(93.6-155.9)	<u>Ovary</u>				
Female	55	54.8	100.4	(75.7-130.8)	Female	16	14.6	109.6	(62.6-178.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	8.5	140.9	(72.7-246.1)	Male	9	9.8	92.3	(42.1-175.2)
Female	4	2.6	nc	(nc-nc)	Female	10	11.6	86.4	(41.4-158.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.8	nc	(nc-nc)	Male	143	139.0	102.9	(86.7-121.2)
Female	3	2.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	8.7	69.0	(25.2-150.3)
Male	11	14.2	77.2	(38.5-138.1)	Female	7	5.8	120.8	(48.4-248.8)
Female	13	9.8	133.2	(70.8-227.7)	<u>Testis</u>				
<u>Larynx</u>					Male	7	5.2	135.5	(54.3-279.2)
Male	9	6.0	150.8	(68.8-286.4)	<u>Thyroid</u>				
Female	1	1.7	nc	(nc-nc)	Male	6	3.8	157.8	(57.6-343.5)
<u>Leukemia</u>					Female	12	13.2	91.0	(47.0-159.0)
Male	11	10.8	102.0	(50.8-182.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	15	9.8	153.7	(86.0-253.5)	Female	30	27.8	108.0	(72.8-154.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	6.6	75.5	(24.3-176.2)	Male	487	458.8	106.2	(96.9-116.0)
Female	2	2.7	nc	(nc-nc)	Female	525	463.3	113.3	(103.8-123.4)
<u>Lung and Bronchus</u>									
Male	56	65.3	85.8	(64.8-111.4)					
Female	76	63.3	120.1	(94.6-150.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Needham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	39	36.9	105.7	(75.1-144.4)	Male	27	18.5	145.6	(95.9-211.8)
Female	17	14.7	115.5	(67.2-184.9)	Female	20	15.6	128.6	(78.5-198.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	6.4	141.1	(64.4-267.9)	Male	3	5.3	nc	(nc-nc)
Female	8	6.1	131.6	(56.6-259.3)	Female	7	4.8	146.9	(58.8-302.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.1	nc	(nc-nc)	Male	11	18.0	61.1	(30.4-109.3)
Female	170	139.5	121.8	(104.2-141.6)	Female	20	18.4	109.0	(66.5-168.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	5.7	nc	(nc-nc)	Male	8	13.1	61.2	(26.4-120.6)
<u>Colon / Rectum</u>					Female	3	7.2	nc	(nc-nc)
Male	51	55.3	92.1	(68.6-121.2)	<u>Ovary</u>				
Female	51	62.4	81.7	(60.8-107.4)	Female	17	15.0	113.3	(66.0-181.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	8.9	67.6	(24.7-147.1)	Male	8	10.4	76.7	(33.0-151.1)
Female	3	3.0	nc	(nc-nc)	Female	16	13.1	122.1	(69.8-198.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.4	nc	(nc-nc)	Male	169	142.1	118.9	(101.7-138.3)
Female	1	2.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	9.4	63.8	(23.3-138.8)
Male	19	14.5	131.5	(79.1-205.3)	Female	2	6.8	nc	(nc-nc)
Female	9	10.1	88.8	(40.5-168.7)	<u>Testis</u>				
<u>Larynx</u>					Male	4	3.8	nc	(nc-nc)
Male	1	6.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.8	nc	(nc-nc)	Male	8	3.4	233.6	(100.6-460.4)
<u>Leukemia</u>					Female	13	11.3	114.9	(61.1-196.5)
Male	9	11.1	80.8	(36.9-153.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	10.5	104.5	(52.1-187.1)	Female	21	28.0	75.1	(46.4-114.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	6.7	nc	(nc-nc)	Male	450	474.6	94.8	(86.2-104.0)
Female	6	3.0	202.5	(73.9-440.7)	Female	495	483.8	102.3	(93.5-111.7)
<u>Lung and Bronchus</u>									
Male	42	68.5	61.3	(44.2-82.9)					
Female	59	66.4	88.9	(67.7-114.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Ashford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.0	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	2	2.9	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	0	0.5	nc	(nc-nc)					
Female	1	0.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	97	107.6	90.1	(73.1-109.9)	Male	24	54.0	44.5	(28.5-66.1)
Female	34	44.1	77.2	(53.4-107.9)	Female	22	47.4	46.5	(29.1-70.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	25	19.0	131.5	(85.1-194.1)	Male	20	15.3	131.1	(80.1-202.5)
Female	13	18.6	69.7	(37.1-119.2)	Female	13	14.3	90.7	(48.3-155.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	3.2	nc	(nc-nc)	Male	36	52.9	68.1	(47.7-94.2)
Female	342	409.2	83.6	(74.9-92.9)	Female	44	55.6	79.1	(57.5-106.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	21	17.1	123.2	(76.2-188.3)	Male	38	36.9	103.0	(72.9-141.4)
<u>Colon / Rectum</u>					Female	20	21.4	93.4	(57.0-144.2)
Male	159	160.4	99.1	(84.3-115.8)	<u>Ovary</u>				
Female	173	183.6	94.2	(80.7-109.3)	Female	47	44.4	105.9	(77.8-140.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	29	25.5	113.6	(76.1-163.2)	Male	34	30.1	112.8	(78.1-157.6)
Female	6	8.7	68.7	(25.1-149.6)	Female	49	39.0	125.7	(92.9-166.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	10	8.2	122.2	(58.5-224.7)	Male	385	411.1	93.7	(84.5-103.5)
Female	14	7.6	184.1	(100.6-308.9)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	45	27.2	165.7	(120.8-221.7)
Male	49	41.5	118.0	(87.3-156.0)	Female	27	19.6	137.7	(90.7-200.4)
Female	39	30.6	127.2	(90.5-174.0)	<u>Testis</u>				
<u>Larynx</u>					Male	14	14.0	100.2	(54.7-168.2)
Male	23	17.6	131.0	(83.0-196.6)	<u>Thyroid</u>				
Female	5	5.3	94.1	(30.3-219.6)	Male	12	10.3	117.0	(60.4-204.5)
<u>Leukemia</u>					Female	30	35.3	85.0	(57.3-121.3)
Male	41	33.0	124.2	(89.1-168.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	32	31.4	101.9	(69.7-143.8)	Female	92	82.8	111.1	(89.6-136.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	35	19.2	182.3	(126.9-253.5)	Male	1376	1382.4	99.5	(94.3-104.9)
Female	12	8.8	136.4	(70.4-238.3)	Female	1294	1442.2	89.7	(84.9-94.8)
<u>Lung and Bronchus</u>									
Male	224	200.2	111.9	(97.7-127.5)					
Female	158	204.2	77.4	(65.8-90.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.8	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	5	3.2	154.4	(49.8-360.4)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.2	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.2	nc	(nc-nc)	Male	10	10.9	92.0	(44.1-169.2)
Female	1	0.1	nc	(nc-nc)	Female	11	10.2	107.6	(53.6-192.5)
<u>Lung and Bronchus</u>									
Male	1	1.5	nc	(nc-nc)					
Female	0	1.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	2.0	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	5	6.4	78.6	(25.3-183.5)	Female	1	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.3	nc	(nc-nc)
Male	2	3.0	nc	(nc-nc)	<u>Ovary</u>				
Female	3	2.3	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	8.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.2	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.6	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	11	26.7	41.2	(20.6-73.8)
Female	1	0.1	nc	(nc-nc)	Female	20	20.7	96.6	(59.0-149.1)
<u>Lung and Bronchus</u>									
Male	0	3.8	nc	(nc-nc)					
Female	3	2.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.1	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	2	3.7	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.2	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	6	4.5	132.2	(48.3-287.7)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	2	0.4	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.2	nc	(nc-nc)	Male	12	14.7	81.5	(42.1-142.3)
Female	0	0.1	nc	(nc-nc)	Female	9	11.2	80.3	(36.7-152.5)
<u>Lung and Bronchus</u>									
Male	3	2.0	nc	(nc-nc)					
Female	1	1.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;